MedTrace Logo

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

NCT00496002 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-04-27

No results posted yet for this study

Summary

The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.

Conditions

Interventions

DRUG

Clevudine

DRUG

Adefovir

Sponsors & Collaborators

  • Pharmasset

    lead INDUSTRY

Principal Investigators

  • M. Michelle Berrey, MD, MPH · Pharmasset

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • China
  • Greece
  • Puerto Rico
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496002 on ClinicalTrials.gov